Exegenesis Bio and Modalis sign collaboration to advance MDL-201
Exegenesis Bio and Modalis Therapeutics Corporation announced a research collaboration and license agreement to advance MDL-201 for Duchenne muscular dystrophy.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.